Prognosis of metastatic renal cell carcinoma with first-line interferon- therapy in the era of molecular-targeted therapy

详细信息    查看全文

• 作者：Yoshiaki Kawano ; Wataru Takahashi ; Masatoshi Eto ; Tomomi Kamba ; Hideaki Miyake ; Masato Fujisawa ; Takao Kamai ; Hirotsugu Uemura ; Taiji Tsukamoto ; Haruhito Azuma ; Akio Matsubara ; Kazuo Nishimura ; Tsuyoshi Nakamura ; Osamu Ogawa and Seiji Naito
• 刊名：Cancer Science
• 出版年：2016
• 出版时间：July 2016
• 年：2016
• 卷：107
• 期：7
• 页码：1013-1017
• 全文大小：379K
• ISSN：1349-7006

文摘

The RCC-SELECT study showed the correlation between single nucleotide polymorphisms (SNP) in STAT3 gene and survival in metastatic renal cell carcinoma (mRCC) patients with first-line interferon-α (IFN-α). In that study, even patients with STAT3 SNP linked to shorter overall survival (OS) exhibited remarkably improved prognosis. All 180 patients evaluated in the above study were further analyzed for correlation between OS and demographics/clinicopathological parameters. OS was estimated using the Kaplan–Meier method. Associations between OS and potential prognostic factors were assessed using the log-rank test and the Cox proportional hazards model. The median OS was 42.8 months. Univariate analysis showed that worse Eastern Cooperative Oncology Group-performance status (ECOG-PS), high T stage, regional lymph node metastasis, distant metastasis, higher grade, infiltrative growth pattern, the presence of microscopic vascular invasion (MVI), hypercalcemia, anemia, thrombocytopenia and elevated C-reactive protein were significantly associated with OS. Multivariate analysis revealed that ECOG-PS (hazard ratio [HR] = 3.665, P = 0.0004), hypercalcemia (HR = 6.428, P = 0.0005) and the presence of MVI (HR = 2.668, P = 0.0109) were jointly significant poor prognostic factors. This is the first study analysing prognostic factors of mRCC patients with first-line IFN-α using large cohort of the prospective study. The present study suggests that first-line IFN-α is still a useful therapy for mRCC even in the era of molecular targeted therapy.